Co-Authors
This is a "connection" page, showing publications co-authored by BITA ESMAELI and DIANA BELL.
Connection Strength
2.014
-
Mutational landscape of lacrimal gland carcinomas and implications for treatment. Head Neck. 2016 04; 38 Suppl 1:E724-E729.
Score: 0.520
-
Primary Ewing's sarcoma with orbit involvement: Survival and visual outcomes after eye-sparing multidisciplinary management in eight patients. Head Neck. 2021 12; 43(12):3857-3865.
Score: 0.202
-
Prognostic factors for local recurrence and survival and impact of local treatments on survival in lacrimal gland carcinoma. Br J Ophthalmol. 2021 06; 105(6):768-774.
Score: 0.185
-
Distinct Biological Types of Ocular Adnexal Sebaceous Carcinoma: HPV-Driven and Virus-Negative Tumors Arise through Nonoverlapping Molecular-Genetic Alterations. Clin Cancer Res. 2019 02 15; 25(4):1280-1290.
Score: 0.165
-
Desmoplastic Small Round Cell Tumor Presenting as an Ocular Mass: Unusual Localization and Remarkable Surgical Approach. Curr Oncol Rep. 2017 Oct 18; 19(12):80.
Score: 0.153
-
Next-generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma. J Pathol. 2016 09; 240(1):84-95.
Score: 0.142
-
Eye-sparing multidisciplinary approach for the management of lacrimal gland carcinoma. Head Neck. 2016 08; 38(8):1258-62.
Score: 0.137
-
Primary intraocular ancient schwannoma: a case report and review of the literature. Head Neck. 2014 Apr; 36(4):E36-8.
Score: 0.113
-
Sclerosing polycystic adenosis of the lacrimal gland. Ophthalmology. 2013 Apr; 120(4):873-873.e1.
Score: 0.112
-
Eyelid carcinoma in patients with systemic lymphoma. J Ophthalmic Vis Res. 2010 Jan; 5(1):38-43.
Score: 0.089
-
Correction: Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2022 Apr 14; 28(8):1735.
Score: 0.052
-
Treatment patterns and outcomes of palliative systemic therapy in patients with salivary duct carcinoma and adenocarcinoma, not otherwise specified. Cancer. 2022 02 01; 128(3):509-518.
Score: 0.050
-
Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2021 08 15; 27(16):4557-4565.
Score: 0.049
-
Association of Immunosuppression With Outcomes of Patients With Cutaneous Squamous Cell Carcinoma of the Head and Neck. JAMA Otolaryngol Head Neck Surg. 2020 02 01; 146(2):128-135.
Score: 0.045